Nephrotic syndrome on sickle cell disease: the impact of Hydroxyurea

被引:0
|
作者
Cunha, Margarida [1 ]
Simao, Carla [1 ]
Ferrao, Anabela [1 ]
Palare, Maria Joao [1 ]
机构
[1] Hosp Santa Maria, Pediat, Lisbon, Portugal
关键词
sickle cell disease; nephrotic syndrome; paediatrics; haematology (drugs and medicines); CHILDREN;
D O I
10.1136/bcr-2020-237545
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nephropathy is a common under-recognised complication of sickle cell disease (SCD) and one of the main factors of poor prognosis in these patients. The association between nephrotic syndrome and SCD in children is rare. Strategies for sickle cell nephropathy prevention are still poorly established. Blood pressure control as well as monitoring of microalbuminuria and renal function are mandatory. The use of antiproteinuric drugs, such as anti-ACE inhibitors (ACEis) and hydroxyurea, should be considered in early stages. Here, we report a case of a female adolescent with SCD and inaugural nephrotic syndrome who, after an initial treatment failure with corticotherapy, had a remarkable recovery after treatment with hydroxyurea and ACEis.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] Malignancies in sickle cell disease patients treated with hydroxyurea
    Ferster, A
    Sariban, E
    Meuleman, N
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (02) : 368 - 369
  • [32] Examining the Effectiveness of Hydroxyurea in People with Sickle Cell Disease
    Lanzkron, Sophie
    Haywood, Carlton, Jr.
    Fagan, Peter J.
    Rand, Cynthia S.
    JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED, 2010, 21 (01) : 277 - 286
  • [33] Hydroxyurea Pharmacokinetic Evaluation in Patients with Sickle Cell Disease
    Di Grazia, Daniela
    Mirabella, Cristina
    Chiara, Francesco
    Caudana, Maura
    Agar, Francesco Maximillian Anthony Shelton
    Zanatta, Marina
    Allegra, Sarah
    Bertello, Jenni
    Voi, Vincenzo
    Ferrero, Giovanni Battista
    Abbadessa, Giuliana
    De Francia, Silvia
    PHARMACEUTICALS, 2024, 17 (10)
  • [34] Azoospermia in a patient with sickle cell disease treated with hydroxyurea
    Garozzo, G
    Disca, S
    Fidone, C
    Bonomo, P
    HAEMATOLOGICA, 2000, 85 (11) : 1216 - 1218
  • [35] Hydroxyurea Dosage Classification for Sickle Cell Disease Patients
    Singh, Bikesh Kumar
    Thakkar, Hardik
    PROCEEDINGS OF THE 6TH INTERNATIONAL CONFERENCE ON INVENTIVE COMPUTATION TECHNOLOGIES (ICICT 2021), 2021, : 1289 - 1292
  • [36] Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know
    Rees, Allison L.
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2016, 33 (05) : 339 - 344
  • [37] Parental and Other Factors Associated With Hydroxyurea Use for Pediatric Sickle Cell Disease
    Oyeku, Suzette O.
    Driscoll, M. Catherine
    Cohen, Hillel W.
    Trachtman, Rebecca
    Pashankar, Farzana
    Mullen, Craig
    Giardina, Patricia J.
    Velazco, Nerissa
    Racine, Andrew D.
    Green, Nancy S.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (04) : 653 - 658
  • [38] Electronic Hydroxyurea Adherence: A Multidimensional Electronic Adherence Intervention That Improves Hydroxyurea Adherence in Children With Sickle Cell Disease
    Creary, Susan
    Chisolm, Deena
    Stanek, Joseph
    Hankins, Jane
    O'Brien, Sarah H.
    JMIR MHEALTH AND UHEALTH, 2019, 7 (08):
  • [39] Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea
    Moschovi, M
    Psychou, F
    Menegas, D
    Tsangaris, GT
    Tzortzatou-Stathopoulou, F
    Nikolaidou, P
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2001, 18 (06) : 371 - 376
  • [40] Hydroxyurea-Induced miRNA Expression in Sickle Cell Disease Patients in Africa
    Mnika, Khuthala
    Mazandu, Gaston K.
    Jonas, Mario
    Pule, Gift D.
    Chimusa, Emile R.
    Hanchard, Neil A.
    Wonkam, Ambroise
    FRONTIERS IN GENETICS, 2019, 10